HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial

Current Topics in Medicinal Chemistry

Volumn 4, Issue 10, 2004, Pages 1059-1077

  Johnson, Allison A ^a   Marchand, Christophe ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; CAFFEIC ACID PHENETHYL ESTER; CARBOXYLIC ACID DERIVATIVE; CATECHOL DERIVATIVE; CICHORIC ACID; COMPLESTATIN; FUNGAL PROTEIN; HYDRAZIDE DERIVATIVE; INTEGRACIN A; INTEGRACIN B; INTEGRACIN C; INTEGRAMIDE A; INTEGRAMIDE B; INTEGRASE; INTEGRASE INHIBITOR; ISOSERINE; L 708906; LITHOSPERMIC ACID; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; PEPTIDE DERIVATIVE; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RAG1 PROTEIN; RAG2 PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SESQUITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; VIRUS TRANSMISSION;

ACETOACETATES; ANTI-HIV AGENTS; BIOLOGICAL FACTORS; CAFFEIC ACIDS; CLINICAL TRIALS; FURANS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INDOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OLIGONUCLEOTIDES; PYRROLES; REVERSE TRANSCRIPTASE INHIBITORS; SUCCINATES; TETRAZOLES; TRIAZOLES;

EID: 3042843657     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388394     Document Type: Review

References (104)

1. Melek, M.; Jones, J. M.; O'Dea, M. H.; Pais, G.; Burke, T. R., Jr. et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc. Natl. Acad. Sci. USA 2002, 99, 134-137.
2. Cushman, M.; Sherman, P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem. Biophys. Res. Commun. 1992, 185, 85-90.
3. Carteau, S.; Mouscadet, J.-F.; Goulaouic, H.; Subra, F.; Auclair, C. Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction. Arch. Biochem. Biophys. 1993, 305, 606-610.
4. Fesen, M. R.; Kohn, K. W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad Sci. USA 1993, 90, 2399-2403.
5. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. In Vitro Activity of a New HIV-1 Integrase Inhibitor in Clinical Development. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA. 2002.
6. Young, S. D., et al. Discovery of a Potent HIV Integrase Inhibitor. Poster presented at AIDS 2002 Meeting. 2002.
7. Nair, V. HIV integrase as a target for antiviral chemotherapy. Reviews in Medical Virology 2002, 12, 179-193.
8. Tarrago-Litvak, L.; Andreola, M. L.; Fournier, M.; Nevinsky, G. A.; Parissi, V. et al. Inhibitors of HIV-1 Reverse Transcriptase and Integrase: Classical and Emerging Therapeutical Approaches. Curr. Pharm. Des. 2002, 8, 595-614.
9. d'Angelo, J.; Mouscadet, J. F.; Desmaele, D.; Zouhiri, F.; Leh, H. HIV-1 integrase: the next target for AIDS therapy? Pathol. Biol. (Paris) 2001, 49, 237-246.
10. Neamati, N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Investig. Drugs 2001, 10, 281-296.
11. Neamati, N.; Marchand, C.; Winslow, H. E.; Pommier, Y. Human Immunodeficiency Virus Type 1 Integrase-targeted Inhibitor Design. Antiretroviral Therapy 2001, 87-104.
12. Pommier, Y.; Marchand, C.; Neamati, N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res. 2000, 47, 139-148.
13. Pais, G. C. G.; Burke, T. R., Jr. Novel aryl diketo-containing inhibitors of HIV-1 integrase. Drugs of the Future 2002, 27, 1101-1111.
14. Zheng, R.; Jenkins, T. M.; Craigie, R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc. Natl. Acad. Sci. USA 1996, 93, 13659-13664.
15. Lodi, P. J.; Ernst, J. A.; Kuszewski, J.; Hickman, A. B.; Engelman, A. et al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 1995, 34, 9826-9833.
16. Bujacz, G.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Andrake, M. et al. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 1997, 272, 18161-18168.
17. Esposito, D.; Craigie, R. Sequence selectivity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interactions. EMBO J. 1998, 17, 5832-5843.
18. Jenkins, T. M.; Esposito, D.; Engelman, A.; Craigie, R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 1997, 16, 6849-6859.
19. Heuer, T. S.; Brown, P. O. Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. Biochemistry 1997, 36, 10655-10665.
20. Heuer, T. S.; Brown, P. O. Photo-Cross-Linking Studies Suggest a Model for the Architecture of an Active Human Immunodeficiency Virus Type 1 Integrase-DNA Complex. Biochemistry 1998, 37, 6667-6678.
21. Ellison, V.; Brown, P. O. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc. Natl. Acad. Sci. USA 1994, 91, 7316-7320.
22. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R. et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity of other polynucleotide transferases. Science 1994, 266, 1981-1986.
23. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R. et al. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95, 9150-9154.
24. Chen, J. C.; Krucinski, J.; Miercke, L. J.; Finer-Moore, J. S.; Tang, A. H. et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA 2000, 97, 8233-8238.
25. Wang, J. Y.; Ling, H.; Yang, W.; Craigie, R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 2001, 20, 7333-7343.
26. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T. et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96, 13040-13043.
27. Lubkowski, J.; Yang, F.; Alexandratos, J.; Wlodawer, A.; Zhao, H. et al. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. USA 1998, 95, 4831-4836.
28. Drake, R.; Neamati, N.; Hong, H.; Pilon, A. A.; Sunthankar, P. et al. Identification of a nucleotide binding site in HIV-1 integrase. Proc. Natl. Acad. Sci. USA 1998, 95, 4170-4175.
29. Engelman, A.; Mizuuchi, K.; Craigie, R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991, 67, 1211-1221.
30. Vink, C.; Oude Groeneger, A. M.; Plasterk, R. H. Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res. 1993, 21, 1419-1425.
31. Marchand, C.; Zhang, X.; Pais, G. C.; Cowansage, K.; Neamati, N. et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 2002, 277, 12596-12603.
32. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
33. Marchand, C.; Neamati, N.; Pommier, Y. In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol. 2001, 340, 624-633.
34. Debyser, Z.; Cherepanov, P.; Pluymers, W.; De Clercq, E. Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol. Biol. 2001, 160, 139-155.
35. Sinha, S.; Pursley, M. H.; Grandgenett, D. P. Efficient concerted integration by recombinant human immunodeficiency virus type 1 integrase without cellular or viral cofactors. J. Virol. 2002, 76, 3105-3113.
36. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin. Ther. Patents 2002, 12, 709-724.
37. Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M. S. et al. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46, 453-456.
38. Sotriffer, C. A.; Ni, H.; McCammon, J. A. HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J. Am. Chem. Soc. 2000, 122, 6136-6137.
39. Sotriffer, C. A.; Ni, H.; McCammon, J. A. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 2000, 43, 4109-4117.
40. Ni, H.; Sotriffer, C. A.; McCammon, J. A. Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: a molecular dynamics study. J. Med. Chem. 2001, 44, 3043-3047.
41. Marchand, C.; Johnson, A. A.; Karki, R. G.; Pais, G. C. G.; Zhang, X. et al. Metal-dependent inhibitionof HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant [F185K/C280S]. Mol. Pharmacol. 2003, 64, 600-609
42. Pais, G. C. G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K. et al. Structure Activity of 3-aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
43. Witvrouw, M., Fikkert, V., Van Maele, B., Pannecouque, C., Neamati, N., Burke, T. R., Pais, G., De Clercq, E., Debyser, Z. Antiviral Resistance to Diketo Acids is Associated with Mutations T66I, L74M and S230R in the HIV Integrase Gene presented at the 15th International Conference on Antiviral Research, Prague, Czech Republic. Antiviral Res. 2002, 53, A18, abstract 45.
44. Espeseth, A. S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J. et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA 2000, 97, 11244-11249.
45. Keseru, G. M.; Kolossvary, I. Fully flexible low-mode docking: application to induced fit in HIV integrase. J. Am. Chem. Soc. 2001, 123, 12708-12709.
46. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W. et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923-4926.
47. Zhang, X.; Pais, G. C. G.; Svarovskaia, E. S.; Marchand, C.; Pathak, V. K. et al. Azido-Containing Aryl Beta-diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1215-1219.
48. Zhang, X.; Marchand, C.; Pommier, Y.; Burke, T. R., Jr. Design and Synthesis of Photoactivatable Aryl Diketo Acid-Containing HIV-1 Integrase Inhibitors as Potential Affinity Probes. Bioorg. Med. Chem. Lett. 2004, 14, 1205-1207.
49. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P. et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 2002, 99, 6661-6666.
50. Jenkins, T. M.; Engelman, A.; Ghirlando, R.; Craigie, R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 1996, 271, 7712-7718.
51. Pluymers, W.; Pannecouque, C.; Fikkert, V.; Neamati, N.; Marchand, C. et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 2000, 38, 641-648.
52. Robinson, W. E.; Cordeiro, M.; Abdel-Malek, S.; Jia, Q.; Chow, S. A. et al. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol. 1996, 50, 846-855.
53. King, P. J.; Ma, G.; Miao, W.; Jia, Q.; McDougall, B. R. et al. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J. Med. Chem. 1999, 42, 497-509.
54. Reinke, R. A.; King, P. J.; Victoria, J. G.; McDougall, B. R.; Ma, G. et al. Dicaffeoyltartaric Acid Analogues Inhibit Human Immunodeficiency Virus Type 1 (HIV-1) Integrase and HIV-1 Replication at Nontoxic Concentrations. J. Med. Chem. 2002, 45, 3669-3683.
55. Hwang, D. J.; Kim, S. N.; Choi, J. H.; Lee, Y. S. Dicaffeoyl- or Digalloyl Pyrrolidine and Furan Derivatives as HIV Integrase Inhibitors. Dioorganic & Medicinal Chemistry 2001, 9, 1429-1437.
56. Robinson, W. E.; Reinecke, M. G.; Abdel-Malek, S.; Jia, Q.; Chow, S. A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA 1996, 93, 6326-6331.
57. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S. et al. Depside and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
58. Molteni, V.; Rhodes, D.; Rubins, K.; Hansen, M.; Bushman, F. D. et al. A new class of HIV-1 integrase inhibitors: the 3,3, 3′,3′-tetramethyl-1,1′-spirobi[indan]-5,5′ ,6,6′-tetrol family. J. Med. Chem. 2000, 43, 2031-2039.
59. Mekouar, K.; Mouscadet, J. F.; Desmaele, D.; Subra, F.; Leh, H. et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 1998, 41, 2846-2857.
60. Zouhiri, F.; Mouscadet, J. F.; Mekouar, K.; Desmaele, D.; Savoure, D. et al. Structure-Activity Relationships and Binding Mode of Styrylquinolines as Potent Inhibitors of HIV-1 Integrase and Replication of HIV-1 in Cell Culture. J. Med. Chem. 2000, 43, 1533-1540.
61. Lee, J. Y.; Park, J. H.; Lee, S. J.; Park, H.; Lee, Y. S. Styrylquinazoline derivatives as HIV-1 integrase inhibitors. Arch. Pharm. (Weinheim) 2002, 335, 277-282.
62. Neamati, N.; Hong, H.; Owen, J. M.; Sunder, S.; Winslow, H. E. et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J. Med. Chem. 1998, 41, 3202-3209.
63. Neamati, N.; Lin, Z.; Karki, R. G.; Orr, A.; Cowansage, K. et al. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45, 5661-5670.
64. Dupont, R.; Jeanson, L.; Mouscadet, J. F.; Cotelle, P. Synthesis and HIV-1 integrase inhibitory activities of catechol and bis- catechol derivatives. Bioorg. Med. Chem. Lett. 2001, 11, 3175-3178.
65. Maurer, K.; Tang, A. H.; Kenyon, G. L.; Leavitt, A. D. Carbonyl J Derivatives: A New Class of HIV-1 Integrase Inhibitors. Bio-Organic Chemistry 2000, 28, 140-155.
66. Singh, S. B.; Zink, D. L.; Heimbach, B.; Genilloud, O.; Teran, A. et al. Structure, stereochemistry, and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase. Org. Lett. 2002, 4, 1123-1126.
67. Singh, S. B.; Herath, K.; Guan, Z.; Zink, D. L.; Dombrowski, A. W. et al. Integramides A and B, two novel non-ribosomal linear peptides containing nine C[alpha]-methyl amino acids produced by fungal fermentations that are inhibitors of HIV-1 integrase. Org. Lett. 2002, 4, 1431-1434.
68. Singh, S. B.; Jayasuriya, H.; Salituro, G. M.; Zink, D. L.; Shafiee, A. et al. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. J. Nat. Prod. 2001, 64, 874-882.
69. Singh, S. B.; Zink, D. L.; Quamina, D. S.; Pelaez, F.; Teran, A.; Felock, P.; Hazuda, D. Integrastatins: structure and HIV-1 integrase inhibitory activities of two novel racemic tetracyclic aromatic heterocycles produced by two fungal species. Tetrahedron Letters 2002, 43, 2351-2354.
70. Singh, S. Z., D. L.; Bills, G. F.; Pelaez F.; Teran, A.; Collado J.; Silverman, K.; Lingham, R.; Felok P.; Hazuda, D. Discovery, structure and HIV-1 integrase inhibitory activities of integracins, novel dimeric alkyl aromatics from Cytonaema sp. Tetrahedron Letters 2002, 43, 1617-1620.
71. Kaneko, I.; Fearon, D. T.; Austen, K. F. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. J. Immunol. 1980, 124, 1194-1198.
72. Chow, S. A.; Vincent, K. A.; Ellison, V.; Brown, P. O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255, 723-726.
73. Zhang, C. F.; Nakamura, N.; Tewtrakul, S.; Hattori, M.; Sun, Q. S. et al. Sesquiterpenes and alkaloids from Lindera chunii and their inhibitory activities against HIV-1 integrase. Chem. Pharm. Bull. (Tokyo) 2002, 50, 1195-1200.
74. Rowley, D. C.; Hansen, M. S.; Rhodes, D.; Sotriffer, C. A.; Ni, H. et al. Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorg. Med. Chem. 2002, 10, 3619-3625.
75. Abd-Elazem, I. S.; Chen, H. S.; Bates, R. B.; Huang, R. C. C. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res. 2002, 55, 91-106.
76. Singh, S. B.; Zink, D. L.; Bills, G. F.; Teran, A.; Silverman, K. C. et al. Four novel bis-(naphtho-gamma-pyrones) isolated from Fusarium species as inhibitors of HIV-1 integrase. Bioorg. Med. Chem. Lett. 2003, 13, 713-717.
77. Puras Lutzke, R. A.; Eppens, N. A.; Weber, P. A.; Houghten, R. A.; Plasterk, R. H. Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. Proc. Natl. Acad. Sci. USA 1995, 92, 11456-11460.
78. Roller, P. P.; Long, Y.-Q.; Lung, F.-D. T.; Pommier, Y.; Neamati, N. Tryptophan-rich integrase inhibitory peptides and peptidomimetics. Peptides 2000; EDK: Paris, 2001; pp 725-726.
79. Maroun, R. G.; Gayet, S.; Benleulmi, M. S.; Porumb, H.; Zargarian, L. et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 2001, 40, 13840-13848.
80. Sourgen, F.; Maroun, R. G.; Frere, V.; Bouziane, M.; Auclair, C. et al. A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Correlated biochemical and spectroscopic results. Eur. J. Biochem. 1996, 240, 765-773.
81. Fermandjian, S.; Maroun, R. S.; Amekraz, B.; Jankowski, C. K. Self-association of an amphipathic helix peptide inhibitor of HIV-1 integrase assessed by electro spray ionization mass spectrometry in trifluoroethanol/water mixtures. Rapid Commun. Mass Spectrom. 2001, 15, 320-324.
82. Maroun, R. G.; Krebs, D.; Roshani, M.; Porumb, H.; Auclair, C. et al. Conformational aspects of HIV-1 integrase inhibition by a peptide derived from the enzyme central domain and by antibodies raised against this peptide. Eur. J. Biochem. 1999, 260, 145-155.
83. de Soultrait, V. R., Caumont, A., Parissi, V., Morellet, V., Ventura, N., Lenoir, M., Litvak, C., Fournier, S., Roques, M. B. A Novel Short Peptide is a Specific Inhibitor of the Human Immunodeficiency Virus Type 1 Integrase. J. Mol. Biol. 2002, 318, 45-58.
84. Bizub-Bender, D.; Kulkosky, J.; Skalka, A. M. Monoclonal antibodies against HIV type 1 integrase: clues to molecular structure. AIDS. Res. Hum. Retrov. 1994, 10, 1105-1115.
85. Asante-Appiah, E.; Skalka, A. M. A metal-induced conformational change and activation of HIV-1 integrase. J. Biol. Chem. 1997, 272, 16196-16205.
86. Yi, J.; Arthur, J. W.; Dunbrack, R. L., Jr.; Skalka, A. M. An inhibitory monoclonal antibody binds at the turn of the helix-turn-helix motif in the N-terminal domain of HIV-1 integrase. J. Biol. Chem. 2000, 275, 38739-38748.
87. Yi, J.; Cheng, H.; Andrake, M. D.; Dunbrack, R. L., Jr.; Roder, H. et al. Mapping the epitope of an inhibitory monoclonal antibody to the C- terminal DNA-binding domain of HIV-1 integrase. J. Biol. Chem. 2002, 277, 12164-12174.
88. BouHamdan, M.; Duan, L. X.; Pomerantz, R. J.; Strayer, D. S. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment [SFv]: delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther. 1999, 6, 660-666.
89. BouHamdan, M.; Kulkosky, J.; Duan, L. X.; Pomerantz, R. J. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment [SFv]: intravirion molecular therapies. J. Hum. Virol. 2000, 3, 6-15.
90. Levy-Mintz, P.; Duan, L.; Zhang, H.; Hu, B.; Dornadula, G. et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J. Virol. 1996, 70, 8821-8832.
91. Ho, W. Z.; Lai, J. P.; Bouhamdan, M.; Duan, L.; Pomerantz, R. J. et al. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single- chain variable fragments. AIDS Res. Hum. Retroviruses 1998, 14, 1573-1580.
92. BouHamdan, M.; Strayer, D. S.; Wei, D.; Mukhtar, M.; Duan, L. X. et al. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co- receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther. 2001, 8, 408-418.
93. Strayer, D. S.; Pomerantz, R. J.; Yu, M.; Rosenzweig, M.; BouHamdan, M.; Yurasov, S.; Johnson, R. P.; Goldstein, H. Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors. Gene Therapy 2000, 7, 886-895.
94. Goldstein, H.; Pettoello-Mantovani, M.; Anderson, C. M.; Cordelier, P.; Pomerantz, R. J. et al. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. J. Infect. Dis. 2002, 185, 1425-1430.
95. Brodin, P.; Pinskaya, M.; Parsch, U.; Bischerour, J.; Leh, H. et al. 6-oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro. Nucleosides Nucleotides Nucleic Acids 2001, 20, 481-486.
96. Brodin, P.; Pinskaya, M.; Buckle, M.; Parsch, U.; Romanova, E. et al. Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. Biochemistry 2002, 41, 1529-1538.
97. de Soultrait, V. R.; Lozach, P. Y.; Altmeyer, R.; Tarrago-Litvak, L.; Litvak, S. et al. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol. 2002, 324, 195-203.
98. Mazumder, A.; Neamati, N.; Ojwang, J. O.; Sunder, S.; Rando, R. F. et al. Inhibition of human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 1996, 43, 13762-13771.
99. Cherepanov, P.; Este, J. A.; Rando, R. F.; Ojwang, J. O.; Reekmans, G. et al. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 1997, 52, 771-780.
100. Jing, N.; Marchand, C.; Liu, J.; Mitra, R.; Hogan, M. E. et al. Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in Vitro. J. Biol. Chem. 2000, 275, 21460-21467.
101. Jing, N.; Xiong, W.; Guan, Y.; Pallansch, L.; Wang, S. Potassium-dependent folding: a key to intracellular delivery of G- quartet oligonucleotides as HIV inhibitors. Biochemistry 2002, 41, 5397-5403.
102. Ouali, M.; Laboulais, C.; Leh, H.; Gill, D.; Desmaele, D. et al. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J. Med. Chem. 2000, 43, 1949-1957.
103. Pannecouque, C.; Pluymers, W.; Van Maele, B.; Tetz, V.; Cherepanov, P. et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 2002, 12, 1169-1177.
104. Krebs, D.; Maroun, R. G.; Sourgen, F.; Troalen, F.; Davoust, D. et al. Helical and coiled-coil-forming properties of peptides derived from and inhibiting human immunodeficiency virus type 1 integrase assessed by 1H- NMR-use of NH temperature coefficients to probe coiled-coil structures. Eur. J. Biochem. 1998, 253, 236-244.